Hopp til hovedinnhold

Kardiovaskulære bivirkninger av cytostatika

Sist revidert:
Sist revidert av:
  1. Haugnes HS, Oldenburg J, Bremnes RM. Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors. Urol Oncol 2015; 33(9): 399-406. PubMed  
  2. Helsedirektoratet. Seneffekter etter kreftbehandling. Rapport IS-2551. Utgitt januar 2017.
  3. Bovelli D, Plataniotis G, Roila F, ESMO Guidelines Working Group. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol 2010;21 Suppl 5:v277-82. academic.oup.com  
  4. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24(27):4448-56. PubMed  
  5. Haugnes HS, Wethal T, Aass N, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010;28:4649-57. PubMed  
  6. Murbraech K, Solheim O, Aulie HM, et al. The impact of cisplatinum-based chemotherapy on right ventricular function and cardiovascular risk factors in female survivors after malignant germ cell cancer. ESC Heart Failure 2015 (in press). www.ncbi.nlm.nih.gov  
  7. Aakhus S. Kardio-onkologi. Indremedisineren på 11.11.2015 i 03, 2015 . indremedisineren.no  
  • Terje Johannessen, professor i allmennmedisin, Trondheim (tilpasning til NEL)